Cell Therapy is a medical treatment in which living cells are administered to a patient to replace, repair, regulate or otherwise modify biological functions. Unlike conventional medicines consisting primarily of defined chemical molecules, cell therapies use viable cells as the therapeutic agent. Examples include haematopoietic stem-cell transplantation, engineered immune-cell therapies and emerging treatments involving differentiated or progenitor cells. Cells may be obtained from the patient, from a donor or from a cell bank and may be administered without modification or after expansion, differentiation, activation or genetic engineering. The term is broad and covers established clinical procedures as well as developing regenerative and immunological technologies.
Autologous Cell Therapy uses the patient's own cells, which can reduce problems of immune rejection and donor compatibility but may involve complex collection and manufacturing. Allogeneic Cell Therapy uses cells from another individual, allowing the possibility of standardised donor-derived products but introducing immune compatibility issues. Syngeneic transplantation between genetically identical individuals is another specialised category. Cell source influences the biology, manufacturing process, safety profile and clinical application. For example, autologous blood-forming stem cells can be collected and returned after intensive treatment, whereas donor immune cells may be used because their immune activity itself is therapeutically valuable.
Cell therapies can act through several mechanisms rather than simply replacing missing tissue. Transplanted cells may engraft and generate functional descendants, as occurs with haematopoietic stem-cell transplantation. Immune cells can recognise and destroy abnormal cells, as in engineered T-cell therapies. Other administered cells may secrete cytokines, growth factors or extracellular vesicles that modify the local environment and influence inflammation or repair, although the relative importance of these mechanisms varies by therapy. Some experimental approaches seek to replace specialised cells lost through degenerative disease, while others aim to modulate immune responses. Understanding the mechanism is essential because the required cell type, dose, route and manufacturing conditions depend on the intended biological action.
Manufacturing is a defining challenge of Cell Therapy. Cells may need to be isolated, selected, activated, genetically modified, expanded and tested before administration. The process must maintain cell identity, viability, purity and functional potency while preventing contamination. Cryopreservation can allow storage and transport but may affect cell viability or function. Autologous products are often manufactured individually, which creates logistical complexity and limits opportunities for large-scale standardisation. Allogeneic products can potentially be produced in batches and stored for later use, but immune compatibility and donor variability must be managed. These characteristics distinguish cell therapies from many conventional pharmaceuticals, which can generally be manufactured as chemically defined, highly uniform batches.
Cell Therapy has important applications in oncology, haematology, immunology and regenerative medicine. Haematopoietic stem-cell transplantation can restore blood formation after intensive therapy, while genetically modified immune-cell therapies can target particular cancer-associated antigens. Other cell-based treatments are being investigated for neurological, cardiovascular, endocrine and musculoskeletal conditions. Evidence varies considerably between applications, and promising laboratory or early-phase results do not establish that a therapy is clinically effective. Appropriate clinical development requires controlled studies that determine safety, dosing, durability and comparative benefit for a specific disease.
Immune reactions are among the principal risks of Cell Therapy. Allogeneic cells can be rejected by the recipient, while donor immune cells can attack recipient tissues in graft-versus-host disease. Conversely, engineered immune cells can sometimes become excessively activated and cause severe inflammatory syndromes or neurological complications. Other risks include infection, thrombosis, abnormal tissue formation, unintended immune effects and complications associated with cell collection or administration. Genetic modification adds another layer of potential risk. Monitoring must therefore address both the cells themselves and the biological responses they provoke after administration.
Regulatory and quality-control requirements are particularly important because cell products are living and can change during manufacturing and storage. Potency assays attempt to determine whether the cells possess the intended biological activity, but measuring potency can be more difficult than measuring the concentration of a conventional drug. Identity testing confirms that the intended cell population is present, while sterility and viability testing address contamination and survival. Chain-of-identity and chain-of-custody controls are especially important for personalised products to ensure that the correct patient's cells are collected, processed and returned. Manufacturing failure can therefore be clinically significant even when the treatment concept itself is biologically sound.
Cell Therapy is often confused with Stem Cell Therapy, but the concepts are not identical. Stem-cell therapy is a subset of cell therapy involving stem cells, whereas cell therapy also includes mature immune cells and other specialised or progenitor cells. Cell Therapy also differs from Gene Therapy, although the two can be combined when cells are genetically modified before administration.
It differs from tissue engineering because tissue engineering generally seeks to construct or regenerate organised tissue using combinations of cells, scaffolds and signalling environments, while cell therapy may administer cells without creating a structured tissue. A common misconception is that injected cells automatically become the desired tissue; in reality, survival, migration, differentiation, integration and functional control are major biological challenges.
